Abstract:The application of haploidentical hematopoietic stem cell transplantation (HSCT) with mesenchymal stem cell (MSC) infusion as a treatment regimen for severe aplastic anemia (SAA) has been reported to be efficacious in single-arm trials. However, it is difficult to assess without comparing the results with those from a first-line, matched-sibling HSCT. Herein, we retrospectively reviewed 91 patients with acquired SAA. They received HSCT from haploidentical donors combined with MSC transfer (HID group). We compared these patients with 103 others who received first-line matched-sibling HSCT (MSD group) to evaluate relative treatment efficacy. Compared with the patients in the MSD group, those in the HID group presented with higher incidences of grades II-IV and III-IV acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD) (p < 0.05). However, the incidence of myeloid and platelet engraftment, graft failure, poor graft function, and extensive cGvHD were comparable for both groups. The median follow-up was 36.6 months and the 3-year overall survival rate was similar for both groups (83.5% versus 79.1%). Univariate and multivariate analyses revealed that time intervals greater than 4 months from diagnosis to transplantation, experienced graft failure, poor graft function, or grade III-IV aGvHD were significantly associated with adverse outcomes. All HID patients received MSC co-transplantation with hematopoietic stem cells. However, the infused MSCs were derived from umbilical cord (UC-MSC group; 43 patients) or bone marrow (BM-MSC group; 48 patients) and were administered at different medical centers. We first compared the outcomes between the two groups and detected that the BM-MSC group exhibited lower incidences of grade III-IV aGvHD and cGvHD (p < 0.05). This study suggests that co-transplantation of hematopoietic and MSCs significantly reduces the risk and incidence of graft rejection and may effectively improve overall survival in patients with SAA even in the absence of closely related histocompatible donor material.

Reduced Intensity Conditioning, Combined Transplantation of Haploidentical Hematopoietic Stem Cells and Mesenchymal Stem Cells in Patients with Severe Aplastic Anemia.

Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia

Clinical observation of haploidentical-hematopoietic stem cell transplantation combined with human umbilical cord-derived mesenchymal stem cells for severe aplastic anemia-II]

RETRACTED ARTICLE: Cotransplantation of Human Umbilical Cord Mesenchymal and Haplo-Hematopoietic Stem Cells in Patients with Severe Aplastic Anemia

Co-transplantation of Mesenchymal Stem Cells Makes Haploidentical HSCT a Potential Comparable Therapy with Matched Sibling Donor HSCT for Patients with Severe Aplastic Anemia

Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results

Treatment of Severe Aplastic Anemia with Transplantation of Combined Haploidentical Hematopoietic Stem Cells and Mesenchymal Stem Cells: A Case Report

Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Severe Aplastic Anemia

Efficacy and Safety of Combined Immunosuppressive Therapy Plus Umbilical Cord Blood Infusion in Severe Aplastic Anemia Patients: A Cohort Study

Infusion of haploidentical hematopoietic stem cells combined with mesenchymal stem cells for treatment of severe aplastic anemia in adult patients yields curative effects

Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD.

Haploidentical peripheral blood hematopoietic stem cell transplantation for treatment of severe aplastic anemia

HLA-matched Sibling Transplantation with G-CSF Mobilized PBSCs and BM Decreases GVHD in Adult Patients with Severe Aplastic Anemia

Haplo-Identical Transplantation for Acquired Severe Aplastic Anaemia in A Multicentre Prospective Study

Long-term Outcome of HLA-haploidentical Hematopoietic SCT Without in Vitro T-cell Depletion for Adult Severe Aplastic Anemia after Modified Conditioning and Supportive Therapy.

Efficacy of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia: a Report of 40 Cases

Unmanipulated Haploidentical Transplantation Conditioning with Busulfan, Cyclophosphamide and Anti-Thymoglobulin for Adult Severe Aplastic Anaemia

Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Severe Aplastic Anemia: A Multicenter Study.

Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA

A Novel Protocol for Haploidentical Hematopoietic SCT Without in Vitro T-cell Depletion in the Treatment of Severe Acquired Aplastic Anemia

Cotransplantation of Haploidentical Mesenchymal Stem Cells to Reduce the Risk of Graft Failure in a Patient with Refractory Severe Aplastic Anemia